Phase
Condition
Cardiac Ischemia
Blood Clots
Stroke
Treatment
Selective Intra-arterial Cooling Infusion (IA-SCI)
Clinical Study ID
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria
Age ≥ 18 and ≤ 80.
Clinical signs consistent with acute ischemic stroke with large vessel occlusion in the anterior circulation (intracranial segment of the internal carotid artery, middle cerebral artery M1 segment) demonstrated with CTA/MRA/DSA.
NIHSS score obtained prior to randomization ≥ 6 and ≤ 25.
Modified Rankin Scale ≤ 1 prior to qualifying stroke.
Arterial puncture performed within 24 hours from symptom onset or LKW.
For the patients with symptom onset within 6 hours, the ASPECT score ≥ 6; for the patients with onset within 6-24 hours, the therapy should meet the imaging criteria of DAWN or DEFUSE-3 trial.
Patient/Legally Authorized Representative has signed the Informed Consent Form.
Exclusion Criteria
Baseline CT/MRI confirms the presence of multiple vascular territory acute strokes.
Baseline CT/MRI confirms the presence of arterial dissection.
Evidence of intracranial hemorrhage or hemorrhagic transformation before thrombectomy.
Known allergies or intolerances to antiplatelet agents, anticoagulation drugs, iodinated contrast and/or anesthetics.
Severe infection (e.g. sepsis) or multiple organ failure.
Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with INR > 3. Patients on factor Xa inhibitor for 48 hours ago must have a normal APTT.
Baseline platelet count < 50 × 10^9/L.
Blood glucose concentration<50 mg/dL (2.7 mmol/L) or >400 mg/dL (22.2 mmol/L).
Refractory hypertension that is difficult to control by medication (Defined as persistent systolic blood pressure>185 mmHg or diastolic blood pressure>110 mmHg).
Previous NHYA>1.
Untreated moderate or severe coronary artery stenosis, or previous coronary artery bypass surgery.
Undergoing hemodialysis or peritoneal dialysis; known severe renal insufficiency with glomerular filtration rate < 30 mL/min or serum creatinine >220 mmol/L (2.5 mg/dL).
Known intracranial aneurysm, and cerebral arteriovenous malformation.
Malignant brain tumor or CNS infection.
Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations (e.g., dementia or mental illness)
Female who is pregnant or lactating at time of admission.
Anticipated life expectancy < 6 months.
Current participation in another investigational drug or device study.
For other reasons, the responsible clinicians believe that the patient is not suitable for continued treatment.
Study Design
Study Description
Connect with a study center
The Second Hospital and Clinical Medical School, Lanzhou University
Lanzhou, Gan Su
ChinaActive - Recruiting
Department of Neurosurgery, Nanshi Hospital of Nanyang
Nanyang, He Nan
ChinaActive - Recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiang Su
ChinaActive - Recruiting
Beijing Shijitan Hospital, Capital Medical University
Beijing,
ChinaActive - Recruiting
Peking University Internation Hospital
Beijing,
ChinaActive - Recruiting
967 Hospital of the Joint Logistics Support Force of PLA
Dalian,
ChinaActive - Recruiting
Dalian Municipal Central Hospital
Dalian,
ChinaActive - Recruiting
The First Affiliated Hospital of Harbin Medical University
Ha'erbin,
ChinaActive - Recruiting
Affiliated Hospital of Inner Mongolia University for the Nationalities
Tongliao,
ChinaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.